Literature DB >> 8855826

Normal hepatic insulin sensitivity in lean, mild noninsulin-dependent diabetic patients.

J Pigon1, A Giacca, C G Ostenson, L Lam, M Vranic, S Efendic.   

Abstract

We studied hepatic and extrahepatic insulin sensitivity and insulin release in seven nonobese patients with mild noninsulin-dependent diabetes mellitus (NIDDM) and 10 control subjects, matched for age, body mass index, and physical fitness. Glucose turnover was studied during sequential hyperinsulinemic euglycemic clamps (insulin infusion, 0.25 and 1.0 mU/kg BW.min), applying the hot-GINF (tracer-enriched glucose infusion) technique and using [6-3H]glucose. Hepatic glucose production was lower in hyperglycemic NIDDM patients during the basal period (P < 0.01), but was equivalent at similar glucose and insulin levels attained during both clamps. In contrast, during the low and high insulin clamps, glucose utilization was lower in NIDDM [14.90 +/- 1.00 vs. 17.24 +/- 0.83 (P < 0.01) and 41.37 +/- 3.05 vs. 50.54 +/- 3.61 mumol/kg BW.min (P < 0.01)]. Accordingly, the glucose infusion rate necessary to maintain euglycemia was lower in NIDDM [7.72 +/- 2.00 vs. 10.68 +/- 1.17 (P < 0.05) and 42.14 +/- 4.50 vs. 51.60 +/- 4.28 mumol/kg BW.min (P < 0.01)]. There was, however, a considerable overlap between patients and controls in the parameters describing insulin sensitivity. The insulin response to orally administered glucose as well as that to a standardized glucose infusion test (GIT) were diminished in NIDDM [average incremental insulin secretion during an oral glucose tolerance test, 88 +/- 28 vs. 251 +/- 50 pmol/L.min (P < 0.05); during first 10 min of GIT, 7 +/- 16 vs. 234 +/- 29 pmol/L.min (P < 0.001)]. There was no overlap in acute phase insulin secretion during the GIT between the groups. In conclusion, nonobese, mild NIDDM patients showed no impairment in hepatic, but a slight reduction in extrahepatic insulin sensitivity, with extensive overlap between diabetic and control subjects. In contrast, impairment of insulin release was very pronounced and without overlap.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8855826     DOI: 10.1210/jcem.81.10.8855826

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  The role of the liver in type 2 diabetes.

Authors:  Peter Staehr; Ole Hother-Nielsen; Henning Beck-Nielsen
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

2.  Increased gluconeogenesis in youth with newly diagnosed type 2 diabetes.

Authors:  Stephanie T Chung; Daniel S Hsia; Shaji K Chacko; Luisa M Rodriguez; Morey W Haymond
Journal:  Diabetologia       Date:  2014-12-03       Impact factor: 10.122

Review 3.  Increasing incidence of type 2 diabetes in children and adolescents: treatment considerations.

Authors:  Arlan L Rosenbloom
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

4.  Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in Type 2 diabetes.

Authors:  D Tripathy; K F Eriksson; M Orho-Melander; J Fredriksson; G Ahlqvist; L Groop
Journal:  Diabetologia       Date:  2004-04-28       Impact factor: 10.122

5.  Major Pathophysiology in Prediabetes and Type 2 Diabetes: Decreased Insulin in Lean and Insulin Resistance in Obese.

Authors:  Udaya M Kabadi
Journal:  J Endocr Soc       Date:  2017-05-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.